Bayer's Legal Calendar Slips Again, Yet the Stock's Rally Keeps Its Footing
Published on 08/08/2026 at 22:11 | Redaktion boerse-global.de
The wait for clarity on Bayer's multibillion-dollar Roundup settlement just got a little longer. A Missouri district court overseeing the proposed agreement has pushed the final approval hearing from August 19 to September 14, a postponement announced Thursday that continues a familiar pattern of delays in the long-running glyphosate saga. The extra weeks are meant to give both sides time to process a wave of opt-out revocation requests that swelled after a favorable US Supreme Court ruling in the Durnell case.
Investors, however, have taken the news in stride. The shares closed Friday at EUR 49.90, up 1.05 percent on the day and 3.14 percent higher on the week — hardly the reaction of a market rattled by another procedural setback. The resilience speaks to a broader shift in sentiment around the Leverkusen-based conglomerate, where improving fundamentals are increasingly competing with legal overhangs for investors' attention.
Q2 Numbers Give Analysts Something to Cheer
The optimism has a concrete foundation: second-quarter results released Thursday beat expectations and prompted a flurry of target revisions. Revenue rose 2.2 percent to EUR 10.872 billion, while EBITDA before special items climbed 1.9 percent to EUR 2.144 billion. The core earnings per share figure fell 16.7 percent to EUR 0.95, dragged down by elevated litigation payments that pushed free cash flow into negative territory. Net profit, however, swung to EUR 219 million from a loss in the year-ago quarter.
Goldman Sachs analyst James Quigley lifted his price target from EUR 62.50 to EUR 63.50 on Wednesday, reiterating a "Buy" rating and citing a strong financial trajectory. His path to the new target runs through a robust pharma franchise, full resolution of glyphosate litigation, and — over the medium to long term — the potential elimination of the conglomerate discount in a breakup scenario. JPMorgan's Richard Vosser also stayed constructive, holding an "Overweight" rating with a EUR 50 target and pointing to solid results and a confirmed outlook that support slightly rising expectations for the full year. All told, three major houses raised their targets in the same week, a signal that Wall Street is increasingly warming to the operational recovery story.
Should investors sell immediately? Or is it worth buying Bayer?
Not everyone is convinced. Jefferies and Berenberg both maintain "Hold" ratings with targets of EUR 46 and EUR 55 respectively, reflecting a wide dispersion of views on how the legal outcome gets priced in. The bulls see resolution on the horizon; the cautious camp notes that delays have a way of compounding.
Crop Science Carries the Quarter
The strongest operational momentum came from the Crop Science division, where currency- and portfolio-adjusted sales grew 3.5 percent, powered by a 16.9 percent jump in soybean seed and a 69.2 percent surge in cotton seed following the reinstatement of the Dicamba label in the US. Pharma grew a more modest 0.8 percent, with EBITDA slightly softer in the segment. Late July also brought a regulatory filing in China for an additional indication of Kerendia, adding another potential pipeline driver alongside ongoing studies.
Management used the quarterly update to tighten its debt outlook. The net financial debt forecast for year-end now stands at EUR 29 to 30 billion, down from a prior range of EUR 32 to 33 billion. Currency-adjusted guidance for 2026 remains intact, with revenue projected between EUR 44.7 and 46.7 billion and core earnings per share of EUR 4.20 to 4.70. CEO Bill Anderson said operations are fully on track to meet the annual targets, and that the glyphosate containment strategy rests on a solid foundation, with key milestones still ahead.
Apollo Deal Reshapes the Balance Sheet
The improved debt picture owes much to a transaction completed July 10, when Bayer transferred a minority stake in a newly formed entity housing its reversible long-acting contraception business to Apollo. The deal secured EUR 3.0 billion in fresh equity, with Bayer retaining majority ownership and full operational control. Closing is expected in the third quarter of 2026. Days earlier, on July 2, the company had also carved out its US glyphosate business — separate moves that together show a balance sheet being reengineered on multiple fronts.
A September Date to Watch
The settlement itself, if approved, would involve tiered and capped payments totaling up to USD 7.25 billion spread over as many as 21 years. The September 14 hearing now becomes the next critical marker for investors tracking the legal calendar.
Bayer at a turning point? This analysis reveals what investors need to know now.
Chart-wise, the stock remains in a notable uptrend despite the uncertainty. Year-to-date, Bayer has gained 34.83 percent, making it one of the DAX's standout performers. The gap to the 52-week high of EUR 53.86, set in early July, stands at 7.35 percent — a measure of how much further the shares could travel if the legal clouds continue to lift.
For now, the stock looks set to oscillate between the bullish targets from Goldman Sachs and Deutsche Bank — the latter reaffirming a EUR 60 price objective — and the more cautious stances from Jefferies and Berenberg. It is a pattern that has defined Bayer's trading for months, and one that September's hearing may finally begin to break.
Ad
Bayer Stock: New Analysis - 8 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
